Guggenheim Maintains Buy on Inventiva, Raises Price Target to $14
9/15/2026
Impact: 75
Healthcare
Guggenheim analyst Seamus Fernandez has reiterated a Buy rating on Inventiva (NASDAQ: IVA) and increased the price target from $11 to $14. This adjustment reflects a positive outlook for the company's performance in the market.
AI summary, not financial advice
Share: